- Home
- ACIC vs ERAS Comparison
ACIC vs ERAS Comparison
Compare ACIC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIC
- ERAS
- Stock Information
- Founded
- ACIC 1999
- ERAS 2018
- Country
- ACIC United States
- ERAS United States
- Employees
- ACIC N/A
- ERAS N/A
- Industry
- ACIC Property-Casualty Insurers
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- ACIC Finance
- ERAS Health Care
- Exchange
- ACIC Nasdaq
- ERAS Nasdaq
- Market Cap
- ACIC 556.0M
- ERAS 439.7M
- IPO Year
- ACIC N/A
- ERAS 2021
- Fundamental
- Price
- ACIC $11.24
- ERAS $1.70
- Analyst Decision
- ACIC Buy
- ERAS Buy
- Analyst Count
- ACIC 1
- ERAS 6
- Target Price
- ACIC $16.00
- ERAS $3.83
- AVG Volume (30 Days)
- ACIC 172.0K
- ERAS 964.1K
- Earning Date
- ACIC 11-05-2025
- ERAS 11-11-2025
- Dividend Yield
- ACIC 4.60%
- ERAS N/A
- EPS Growth
- ACIC 14.01
- ERAS N/A
- EPS
- ACIC 1.63
- ERAS N/A
- Revenue
- ACIC $320,072,000.00
- ERAS N/A
- Revenue This Year
- ACIC $4.91
- ERAS N/A
- Revenue Next Year
- ACIC $4.16
- ERAS N/A
- P/E Ratio
- ACIC $6.66
- ERAS N/A
- Revenue Growth
- ACIC 33.90
- ERAS N/A
- 52 Week Low
- ACIC $8.82
- ERAS $1.01
- 52 Week High
- ACIC $15.08
- ERAS $3.31
- Technical
- Relative Strength Index (RSI)
- ACIC 54.58
- ERAS 57.89
- Support Level
- ACIC $10.71
- ERAS $1.53
- Resistance Level
- ACIC $11.17
- ERAS $1.69
- Average True Range (ATR)
- ACIC 0.34
- ERAS 0.10
- MACD
- ACIC -0.02
- ERAS 0.01
- Stochastic Oscillator
- ACIC 47.97
- ERAS 76.60
About ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.